BPC-157: What the Preclinical Evidence Actually Shows

BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric protective protein, investigated in preclinical models of tissue repair, gastrointestinal protection, and angiogenic signalling. No randomised controlled human trials have been published. All published efficacy data is from animal or in vitro work.

What is BPC-157 and where does it come from?

BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a region of human gastric juice protein known as Body Protection Compound. It was first described by Sikirić and colleagues at the University of Zagreb in 1993. Notably, it is stable in gastric environments — a property unusual for most peptides, which are rapidly degraded by stomach acid and proteases.

Proposed mechanisms

The BPC-157 literature attributes activity to three converging pathways:

Nitric oxide system modulation

BPC-157 appears to interact with the nitric oxide (NO) system in a context-dependent manner, upregulating NO signalling under some conditions and downregulating it under others. This affects vasodilation, blood flow, and inflammatory cascades.

Growth factor signalling

Preclinical models show upregulation of growth hormone receptor expression in tendon fibroblasts and influence on VEGF receptor activity, the latter linked to angiogenesis.

FAK-paxillin pathway activation

BPC-157 activates the focal adhesion kinase pathway, which is critical for cell migration, adhesion, and survival in tissue repair.

Tissue-specific preclinical findings

The preclinical literature spans tendon, ligament, muscle, bone, gastrointestinal, vascular, and central nervous system models. The breadth is striking, but most studies share methodological characteristics: small sample sizes, single-laboratory replication, and rodent-only models. Independent replication across laboratories is comparatively rare.

What the evidence does not show

The most important limitation: no randomised controlled trials in humans have been published. All published BPC-157 efficacy data comes from animal or in vitro work. Anecdotal human reports circulate widely online but do not constitute clinical evidence.

For research purposes, the preclinical literature is sufficient to make BPC-157 a useful tool compound for tissue-signalling investigations. For therapeutic claims, the evidence base does not support them — and any supplier or commentator making such claims is overreaching.

Australian regulatory status

BPC-157 is listed in Appendix D of the TGA Poisons Standard, which applies additional record-keeping and supply controls beyond standard Schedule 4. Pillar Research complies fully with these controls. Read more in our Australian regulatory guide.

Research use

BPC-157 10mg is available in our research catalogue, independently HPLC tested at >99.8% purity with batch-specific COA. It is also offered as part of a BPC-157 + TB-500 blend for comparative tissue-signalling research.

Key references

• Sikirić P et al. Curr Pharm Des. 2018;24(18):2002-2030.
• Chang CH et al. J Appl Physiol. 2011;110(3):774-780.
• Keremi B et al. J Physiol Pharmacol. 2009;60(Suppl 7):191-196.